Community hub
Recent from talks
Knowledge base stats:
Talk channels stats:
Members stats:
David Gobel
David Gobel (born 1952 in Baltimore, Maryland) is an American philanthropist, entrepreneur, inventor, and futurist. He is co-founder and CEO of the Methuselah Foundation, CEO of the Methuselah Fund, and one of the first to publicly advance the idea of longevity escape velocity, even before this term was formulated.
David Gobel heads the Methuselah Foundation, a medical charity that was organized in 2000 and is based in Springfield, VA. Under Gobel's leadership, Methuselah has invested millions of dollars to support research and development in regenerative medicine, and is actively involved in efforts to change how the public thinks about extending the healthy human lifespan.
With co-founders Dane Gobel and Aubrey de Grey, Gobel established Methuselah in order to, as stated on its original website, "shed light on the processes of aging and find ways to extend healthy life."
The organization works in a variety of ways: Incubating companies that are developing breakthrough technologies, supporting mission-relevant ventures that promote longevity research, funding such research directly and supporting projects and prizes to accelerate breakthroughs in longevity.iii
Through Methuselah, Gobel, and de Grey established research programs focused on advanced human bioremedial biology at Rice University and Arizona State University—the world's first use of environmental remediation techniques to be directed at reversing "pollution" in human cells.
Gobel also oversaw Methuselah's funding of the 2015 sequencing of the longest-lived mammal, the bowhead whale, which can live more than 200 years. The objective of this work was to identify any protective molecular adaptations within the species that may be relevant to age-related diseases, particularly cancer.iv
In 2021, Methuselah contributed $1 million to Albert Einstein College of Medicine to fund the development of engineered replacement brain structures to correct age-related neurological damage without losing memories or self identity.v vi
Gobel has directed Methuselah's investment in a variety of companies developing breakthrough technologies and clinical interventions in regenerative medicine. These companies include:
Hub AI
David Gobel AI simulator
(@David Gobel_simulator)
David Gobel
David Gobel (born 1952 in Baltimore, Maryland) is an American philanthropist, entrepreneur, inventor, and futurist. He is co-founder and CEO of the Methuselah Foundation, CEO of the Methuselah Fund, and one of the first to publicly advance the idea of longevity escape velocity, even before this term was formulated.
David Gobel heads the Methuselah Foundation, a medical charity that was organized in 2000 and is based in Springfield, VA. Under Gobel's leadership, Methuselah has invested millions of dollars to support research and development in regenerative medicine, and is actively involved in efforts to change how the public thinks about extending the healthy human lifespan.
With co-founders Dane Gobel and Aubrey de Grey, Gobel established Methuselah in order to, as stated on its original website, "shed light on the processes of aging and find ways to extend healthy life."
The organization works in a variety of ways: Incubating companies that are developing breakthrough technologies, supporting mission-relevant ventures that promote longevity research, funding such research directly and supporting projects and prizes to accelerate breakthroughs in longevity.iii
Through Methuselah, Gobel, and de Grey established research programs focused on advanced human bioremedial biology at Rice University and Arizona State University—the world's first use of environmental remediation techniques to be directed at reversing "pollution" in human cells.
Gobel also oversaw Methuselah's funding of the 2015 sequencing of the longest-lived mammal, the bowhead whale, which can live more than 200 years. The objective of this work was to identify any protective molecular adaptations within the species that may be relevant to age-related diseases, particularly cancer.iv
In 2021, Methuselah contributed $1 million to Albert Einstein College of Medicine to fund the development of engineered replacement brain structures to correct age-related neurological damage without losing memories or self identity.v vi
Gobel has directed Methuselah's investment in a variety of companies developing breakthrough technologies and clinical interventions in regenerative medicine. These companies include: